Jeffrey Patton

693 total citations
28 papers, 518 citations indexed

About

Jeffrey Patton is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Jeffrey Patton has authored 28 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Hematology. Recurrent topics in Jeffrey Patton's work include Cancer Treatment and Pharmacology (4 papers), Erythropoietin and Anemia Treatment (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Jeffrey Patton is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Erythropoietin and Anemia Treatment (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Jeffrey Patton collaborates with scholars based in United States and United Kingdom. Jeffrey Patton's co-authors include John D. Hainsworth, F. Anthony Greco, David R. Spigel, Howard A. Burris, Denise A. Yardley, C. Farley, N. W. Peacock, Eric Raefsky, Joel Wallace and Timothy Reeves and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Jeffrey Patton

27 papers receiving 504 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey Patton United States 11 203 202 109 94 68 28 518
Ketki Tendulkar United States 13 345 1.7× 265 1.3× 65 0.6× 167 1.8× 47 0.7× 22 645
Marie Bretagne France 10 145 0.7× 95 0.5× 59 0.5× 91 1.0× 50 0.7× 31 443
Shande Tang United States 10 152 0.7× 97 0.5× 167 1.5× 137 1.5× 62 0.9× 15 454
Sarah Skeoch United Kingdom 9 130 0.6× 239 1.2× 31 0.3× 70 0.7× 44 0.6× 19 631
Stefano Battaglia Italy 12 123 0.6× 277 1.4× 74 0.7× 264 2.8× 88 1.3× 18 603
Francis Donaldson United Kingdom 8 222 1.1× 174 0.9× 40 0.4× 142 1.5× 46 0.7× 10 529
Frank Peters Netherlands 13 425 2.1× 323 1.6× 40 0.4× 76 0.8× 70 1.0× 32 754
Rebecca S. Tidwell United States 11 351 1.7× 199 1.0× 111 1.0× 127 1.4× 78 1.1× 40 617
C. Rusconi Italy 9 142 0.7× 108 0.5× 87 0.8× 57 0.6× 48 0.7× 18 516
J. Bishop Australia 11 331 1.6× 241 1.2× 231 2.1× 112 1.2× 50 0.7× 21 706

Countries citing papers authored by Jeffrey Patton

Since Specialization
Citations

This map shows the geographic impact of Jeffrey Patton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Patton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Patton more than expected).

Fields of papers citing papers by Jeffrey Patton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Patton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Patton. The network helps show where Jeffrey Patton may publish in the future.

Co-authorship network of co-authors of Jeffrey Patton

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Patton. A scholar is included among the top collaborators of Jeffrey Patton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Patton. Jeffrey Patton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Blakely, L. Johnetta, et al.. (2019). Launch of telemedicine in community oncology practice.. Journal of Clinical Oncology. 37(27_suppl). 275–275. 1 indexed citations
3.
Dickson, Natalie R., et al.. (2019). Impact of community practice on providing in-patient oncology and hematology consults via telemedicine to remote rural hospital.. Journal of Clinical Oncology. 37(27_suppl). 278–278. 1 indexed citations
4.
Bendell, Johanna C., Suzanne F. Jones, Lowell L. Hart, et al.. (2015). A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors. Cancer Investigation. 33(10). 477–482. 17 indexed citations
5.
Pant, Shubham, Lowell L. Hart, Johanna C. Bendell, et al.. (2013). Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 3564–3564. 1 indexed citations
6.
Spigel, David R., John D. Hainsworth, John H. Barton, et al.. (2010). Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(6). 841–845. 5 indexed citations
7.
Yardley, Denise A., Michael McCleod, Fred Schreiber, et al.. (2010). A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer. Cancer Investigation. 28(9). 925–931. 17 indexed citations
8.
Spigel, David R., F. Anthony Greco, Denise A. Yardley, et al.. (2007). Phase II trial of irinotecan, carboplatin, and bevacizumab in patients with limited-stage small cell lung cancer. Journal of Clinical Oncology. 25(18_suppl). 18133–18133. 12 indexed citations
9.
Hainsworth, John D., et al.. (2006). Topotecan, paclitaxel, and carboplatin in advanced ovarian cancer: A phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 24(18_suppl). 15015–15015. 3 indexed citations
10.
Mun, Yong, et al.. (2006). Advances in conducting retrospective chart review studies: use of electronic report forms and database in a community study in anemic patients with myelodysplastic syndrome.. PubMed. 3(6 Suppl 4). 12–3. 2 indexed citations
11.
12.
Peacock, N. W., David R. Spigel, John D. Hainsworth, et al.. (2006). A phase II trial of biweekly pemetrexed (P) and gemcitabine (G) in the first-line treatment (tx) of patients (pts) with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 24(18_suppl). 17054–17054. 3 indexed citations
13.
Patton, Jeffrey, et al.. (2006). A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.. PubMed. 3(6). 419–26. 13 indexed citations
14.
Hainsworth, John D., Jeffrey A. Sosman, David R. Spigel, et al.. (2005). Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trial. Journal of Clinical Oncology. 23(16_suppl). 4542–4542. 19 indexed citations
15.
Patton, Jeffrey, Timothy Reeves, & Joel Wallace. (2004). Effectiveness of Darbepoetin Alfa Versus Epoetin Alfa in Patients with Chemotherapy-Induced Anemia Treated in Clinical Practice. The Oncologist. 9(4). 451–458. 42 indexed citations
16.
17.
18.
Jones, Suzanne F., John G. Kuhn, F. Anthony Greco, et al.. (2004). Prolonged Intermittent Oral Topotecan in Patients with Refractory and/or Advanced Malignancies. 3(5). 317–324. 1 indexed citations
19.
Patton, Jeffrey, et al.. (1996). Combination Cisplatin and Carboplatin in Advanced Squamous Cell Carcinoma of the Head and Neck. Cancer Investigation. 14(2). 98–102. 1 indexed citations
20.
Patton, Jeffrey, et al.. (1994). Serum lactate dehydrogenase and platelet count predict survival in thrombotic thrombocytopenic purpura. American Journal of Hematology. 47(2). 94–99. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ketki Tendulkar Breakdown of academic impact, for papers by Marie Bretagne Breakdown of academic impact, for papers by Shande Tang Breakdown of academic impact, for papers by Sarah Skeoch Breakdown of academic impact, for papers by Stefano Battaglia Breakdown of academic impact, for papers by Francis Donaldson Breakdown of academic impact, for papers by Frank Peters Breakdown of academic impact, for papers by Rebecca S. Tidwell Breakdown of academic impact, for papers by C. Rusconi Breakdown of academic impact, for papers by J. Bishop
Rankless by CCL
2026